The Indication — Analysis https://theindication.ca Canadian pharmaceutical channel intelligence — the regulatory firehose, monitored, with the read on what each decision means for distribution, reimbursement, and channel strategy. en-CA What the pCPA's GLP-1 decision really signals for specialty distribution https://theindication.ca/a/pcpa-glp1-specialty-distribution https://theindication.ca/a/pcpa-glp1-specialty-distribution A concluded pCPA negotiation on a GLP-1 agonist clears the pricing gate — but the channel is where the margin and risk live. What the decision means for specialty distribution. Sat, 13 Jun 2026 16:00:00 GMT PMPRB's retreat on the new guidelines is a win pharma won't celebrate out loud https://theindication.ca/a/pmprb-guidelines-retreat https://theindication.ca/a/pmprb-guidelines-retreat PMPRB walking back its contested price tests looks like an industry win — but the real effect is on launch sequencing and every downstream reimbursement timeline. Fri, 12 Jun 2026 16:00:00 GMT CADTH's conditional recommendation isn't about the drug. It's a message to the provinces. https://theindication.ca/a/cadth-conditional-rec-message https://theindication.ca/a/cadth-conditional-rec-message A conditional CADTH reimbursement recommendation is a negotiating lever, not a clinical verdict. How the conditions set up the pCPA price negotiation that follows. Thu, 11 Jun 2026 16:00:00 GMT Health Canada's biosimilar NOC starts a clock the originator can't stop https://theindication.ca/a/biosimilar-noc-clock https://theindication.ca/a/biosimilar-noc-clock A biosimilar Notice of Compliance is the starting gun for provincial switching policy. Why the first mandatory-switch decision, not the approval, reshapes channel volume. Tue, 09 Jun 2026 16:00:00 GMT